Recent Quotes (30 days)

You have no recent quotes
chg | %

Oncolytics Biotech Inc.  

(Public, TSE:ONC)   Watch this stock  
Find more results for ONC
0.230
0.000 (0.00%)
Dec 6 - Close
TSE data delayed by 15 mins - Disclaimer
Currency in CAD
Range     -
52 week 0.19 - 0.75
Open     -
Vol / Avg. 0.00/179,020.00
Mkt cap 28.97M
P/E     -
Div/yield     -
EPS -0.11
Shares 120.87M
Beta 0.74
Inst. own     -
Nov 3, 2016
Q3 2016 Oncolytics Biotech Inc Earnings Release
Sep 13, 2016
Oncolytics Biotech Inc at Rodman & Renshaw Global Investment Conference
  

Key stats and ratios

Q3 (Sep '16) 2015
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -67.16% -61.57%
Return on average equity -78.13% -71.30%
Employees 22 -
CDP Score - -

Address

210-1167 Kensington Cres NW
CALGARY, AB T2N 1X7
Canada
+1-403-6707377 (Phone)
+1-403-2830858 (Fax)

Website links

Description

Oncolytics Biotech Inc. is a development-stage company. The Company is focused on the development of REOLYSIN, its cancer therapeutic. The Company's clinical program is made up of a registration program that includes muscle-invasive bladder cancer and glioma cancer, over six randomized Phase II clinical trials and approximately six other investigative clinical trials. The Company focuses on the registration of REOLYSIN in approximately two indications, including the neoadjuvant treatment of muscle-invasive bladder cancer and the treatment of glioblastoma. The Company has conducted a single arm United States Phase II non-small cell lung cancer (NSCLC) trial and a single arm United States Phase II pancreatic cancer trial for REOLYSIN. The Company is also engaged in conducting a Phase Ib trial for REOLYSIN and chemotherapy in combination with pembrolizumab in its Checkpoint Inhibitor Program.

Officers and directors

Wayne F. Pisano Chairman of the Board
Matthew C. Coffey Ph.D. Interim President, Chief Executive Officer, Chief Operating Officer, Director
Kirk J. Look Chief Financial Officer
George M. Gill M.D. Senior Vice President - Regulatory Affairs & Chief Safety Officer
Mary Ann Dillahunty J.D. Vice President - Intellectual Property
Andres A. Gutierrez M.D., PhD. Chief Medical Officer
Alan J. Tuchman M.D. Chief Neuro Oncology Research Officer
Age: 69
Angela Frances Holtham Director
Edwin Levy Ph.D. Director
J. Mark Lievonen Director